While blooming British gardens have long lent a much-needed splash of colour to our grey climes, that could all be about to ...
Ideal Home on MSN3d
I was sceptical, but these expert-approved plants and flowers convinced me that Mocha Mousse, Pantone's Colour of the Year, is the perfect colour for gardensPantone's Colour of the Year for 2025 hasn't just caught the attention of interior designers — gardeners are jumping on the ...
New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Akebia Therapeutics ...
https://www.tipranks.com/news/the-fly/akebia-announces-multiple-positive-business-updates Akebia (AKBA) Therapeutics announced multiple positive business updates. As ...
Akebia received feedback from the U.S. Food and Drug Administration (FDA) on its protocol submission for a label expansion study and is incorporating feedback as appropriate. Akebia expects to begin ...
CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...
Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...
Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), retaining the price target of $7.50. Discover outperforming stocks and invest smarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback